Physician profile
Mark D Smith
NPI 1811919285
$1,021.40
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $34.08 · 2021: $222 · 2022: $66.96 · 2023: $175 · 2024: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $161.46 | 2021-2024 | Twirla |
| Astellas Pharma US INC | $156.10 | 2019-2023 | Veozah |
| Organon LLC | $148.85 | 2022-2024 | |
| Therapeuticsmd, INC. | $141.43 | 2019 | |
| Hologic Sales and Service, LLC | $122.21 | 2019 | |
| Abbvie INC. | $94.01 | 2019-2021 | |
| Exeltis, USA INC. | $29.67 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $21.82 | 2023 | Myfembree |
| Mycovia Pharmaceuticals, INC. | $21.63 | 2022 | |
| Myovant Sciences INC. | $19.17 | 2021 | |
| Shield Therapeutics INC | $18.45 | 2024 | |
| Roche Diagnostics Corporation | $18.31 | 2020 | |
| Ascend Therapeutics US, LLC | $18.18 | 2021 | |
| Avion Pharmaceuticals | $15.77 | 2020 | |
| Exact Sciences Corporation | $14.26 | 2023 | Cologuard Collection Kit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11.80 | 2021 | |
| Mission Pharmacal Company | $8.28 | 2024 | Citranatal Medley |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.